"A Randomized Double-Blind Placebo-Controlled Trial of Botulinum Toxin Type A (BOTOX ) in the Treatment of Hemiplegic Shoulder Pain and Spasticity"
Overview
- Phase
- N/A
- Intervention
- Botulinum Toxin Type A - OnabotulinumtoxinA
- Conditions
- Post-stroke Shoulder Pain and Spasticity
- Sponsor
- Shirley Ryan AbilityLab
- Enrollment
- 21
- Locations
- 1
- Primary Endpoint
- Change in Pain Rating From Baseline to Four Weeks
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
The purpose of this study is to evaluate whether botulinum toxin type A injected into muscles around the shoulder is effective in treating shoulder pain and improving function in patients with shoulder pain and involuntary muscle tightness after a stroke.
Detailed Description
Subjects with shoulder pain and spasticity at the shoulder following a stroke resulting in hemiplegia are eligible for participation. Following an initial screening visit involving a history and physical examination, subjects will be entered in to the study if they have significant spasticity of shoulder internal rotation/adduction associated with pain rated at least a 4 on the VAS for pain. Subjects will also be given a cognitive screening in which they will be asked to rate pain in hypothetical situations. Shoulder pain is a frequent complication following hemiplegic stroke, and may result in further disability. Spasticity is also a complication following stroke . Botulinum toxin is used in the treatment of post-stroke spasticity and may also have pain modulating effects. Participants in this study will be asked to make total of 6 visits over a period of approximately 13 weeks. Eligible subjects will be randomized to 100 to 200 units of botulinum toxin type injected into the pectoralis major at the second visit. If there is significant spasticity for shoulder extension, subjects will also receive injections into the teres major. Subjects will be followed up with assessments of pain, functioning, active and passive range of motion and depression following the initial injection. At the 12 weeks post injection visit, the blinding will be broken and subjects initially injected with placebo will be injected with the active drug. This will be done to give all subjects an opportunity to receive the active drug, as well as to assess the effects of any differences with delayed treatment. All subjects will return 4 weeks later to repeat the same assessments above. Subjects will be called at one year post study enrollment for repeat pain ratings and for information regarding subsequent treatments. .
Investigators
Christina Marciniak
Principal Investigator
Shirley Ryan AbilityLab
Eligibility Criteria
Inclusion Criteria
- •Post stroke greater than 2 months
- •Shoulder pain despite PT/OT interventions
- •Weight greater than 88 lbs
- •Stable medically
- •Spasticity
Exclusion Criteria
- •Myasthenia gravis or other medical conditions that preclude use of botulinum toxin
- •Pregnancy
- •Infection or dermatologic conditions at the injection site
Arms & Interventions
Intramuscular OnabotulinumtoxinA
Injection of Botulinum Toxin type A - onabotulinumtoxinA into specified shoulder muscles at second visit
Intervention: Botulinum Toxin Type A - OnabotulinumtoxinA
Intramuscular Placebo (Saline)
Injection of saline into specified shoulder muscles at Visit 2. Blind broken and subjects were offered study drug if initially in the placebo group, at week 12
Intervention: Placebo (Saline)
Outcomes
Primary Outcomes
Change in Pain Rating From Baseline to Four Weeks
Time Frame: baseline and four weeks
Change scores from patient ratings on the Visual Analogue Scale on 101 mm scale for worst pain, averaged over a week. Ratings performed at baseline and week four. Scale range 0-100 mm. Minimum value 0= No pain, Maximum value 100= worst pain Higher score indicates worse outcome
Secondary Outcomes
- Ability to Perform Hygiene Rating(2,4,12, and 16 weeks)
- Change in Disability Assessment Scale for Hygiene(baseline and 4 weeks post injection)
- Time to Don a Pull Over Shirt(2,4,12, and 16 weeks)